Trial Profile
A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK971086 After a Single Dose and 7 Days of Repeat Dosing in Healthy Adult Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 971086 (Primary)
- Indications Muscular atrophy
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 13 May 2014 New trial record